This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BBI Brickell Biotech (BBI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Brickell Biotech Stock (NASDAQ:BBI) Get Brickell Biotech alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.77▼$0.9352-Week Range N/AVolume31,300 shsAverage Volume206,730 shsMarket Capitalization$6.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado. Read More Receive BBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBI Stock News HeadlinesBrickell hotel sold by royal family member for $55MOctober 19, 2023 | bizjournals.comPaul Simon and Edie Brickell's daughter speaks out following parents' arrestAugust 27, 2023 | dailymail.co.ukAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best." | Brownstone Research (Ad)Seattle Biotech NewsApril 25, 2023 | bizjournals.comNuclear Receptor ROR-Gamma Market Size by 2030April 10, 2023 | marketwatch.comBrickell City CentreMarch 29, 2023 | travel.usnews.comBiotech NewsMarch 24, 2023 | bizjournals.com5 strategies for biotech startups to outlast a market downturnMarch 18, 2023 | techcrunch.comTSee More Headlines BBI Stock Analysis - Frequently Asked Questions How were Brickell Biotech's earnings last quarter? Brickell Biotech, Inc. (NASDAQ:BBI) announced its earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative trailing twelve-month return on equity of 156.10% and a negative net margin of 643.48%. When did Brickell Biotech's stock split? Shares of Brickell Biotech reverse split on Tuesday, July 5th 2022.The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Brickell Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brickell Biotech investors own include Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Alphabet (GOOG), NVIDIA (NVDA), Ocugen (OCGN), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings8/11/2022Today9/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BBI CIK819050 Webwww.brickellbio.com Phone(720) 505-4755Fax858-646-1150Employees16Year Founded2009Profitability EPS (Trailing Twelve Months)($13.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.47 million Net Margins-643.48% Pretax Margin-643.48% Return on Equity-156.10% Return on Assets-128.23% Debt Debt-to-Equity RatioN/A Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual Sales$4.64 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.75 per share Price / BookN/AMiscellaneous Outstanding Shares2,874,000Free Float2,744,000Market Cap$6.75 million OptionableNot Optionable Beta0.02 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BBI) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brickell Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brickell Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.